(AOF) – Implanet, a medical technology company specializing in implants intended for orthopedic surgery and in the distribution of technological medical equipment, announces the launch of a cash capital increase with maintenance of preferential subscription rights (“DPS” ) from shareholders in the amount of 6.384 million euros through the issue of 97.478 million new shares at a unit price of 0.0655 euros corresponding to the closing price on January 3, 2024.
The objectives of the Capital increase aim in particular to ensure the financing of the company’s anticipated cash flow needs for the next 12 months (the financial resources available to the company, at the date of this press release, do not cover its forecast needs for the next 12 months). 12 months) and meet its financial commitments.
Based on current business assumptions and anticipated commercial developments with Sanyou Medical, the company estimates that the Capital increase operation, up to a minimum amount of 5 million euros, would ensure, once achieved, financial visibility of more than 12 months.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.